PITTSBURGH, Dec. 14, 2010 /PRNewswire/ — Dr. Barbara Ward and
others of Weinstein Imaging determined that Breast-Specific Gamma
Imaging/Molecular Breast Imaging (BSGI/MBI) provides additional
information when conventional imaging is indeterminate and greater
confidence is required to improve diagnostic accuracy. The
data from the retrospective study demonstrated that BSGI
contributed significantly to patient management by detecting cancer
in 7 of the 73 patients (9%), and was presented last week at the
San Antonio Breast Cancer Symposium.
BSGI/MBI is a molecular breast imaging technique that is used to
identify early stage cancers by means of a high-resolution, small
field-of-view gamma camera and a radiotracer. Cells with increased
metabolic activity, such as rapidly dividing cancers,
preferentially absorb this tracer and are viewed as dark spots on
the BSGI image. BSGI is a diagnostic complement to mammography, and
is especially helpful for patients with negative or indeterminate
mammograms and an unresolved clinical concern such as indeterminate
densities, new vague calcifications, bloody nipple discharge, focal
breast pain or palpable masses; especially in those of elevated
risk and patients with dense breast tissue.
The study included 73 patients with 79 regions of concern that
were classified as indeterminate following mammography and
ultrasound. There were 7 biopsy proven malignant lesions and
72 benign findings on pathology or follow-up imaging. BSGI
was positive in 7 malignant and 21 benign lesions and negative in
51 benign lesions, yielding a sensitivity of 100% and specificity
of 71%. The study showed that BSGI/MBI is a useful
complimentary tool in the diagnostic work up of patients when a
diagnostic concern remains after negative or indeterminate
conventional imaging.
About Dilon Diagnostics
Dilon Diagnostics, a brand of Dilon Technologies Inc., is
bringing innovative medical imaging
‘/>”/>
